NCT06693986View on ClinicalTrials.gov

Adenovirus (RGDCRAdCOX2F)

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 27, 2024

Primary Completion Date

October 15, 2028

Study Completion Date

October 15, 2029

Conditions
Adenocarcinoma of Pancreas
Interventions
BIOLOGICAL

Replicative Adenovirus Vector (RGDCRAdCOX2F)

"RGDCRAdcox2F (RGD) is a local product and is provided through this study."

Trial Locations (1)

55455

RECRUITING

Masonic Cancer Center, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT06693986 - Adenovirus (RGDCRAdCOX2F) | Biotech Hunter | Biotech Hunter